JNJ-16241199

JNJ-16241199 (R306465) is an orally active, selectivehydroxamate-based histone deacetylase (HDAC) inhibitor, with theIC50of 3.3 nM and 23 nM for HDAC1and HDAC8, respectively.JNJ-16241199induces histone 3 acetylation and strongly increases the expression of p21waf1, cip1 in A2780 ovarian carcinoma cells.JNJ-16241199 inducescell apoptosisand shows anticancer activityin a broad spectrum of human malignancies. JNJ-16241199 can be used for cancer study[1].

Product Specifications

CAS Number

[604769-01-9]

Product Name Alternative

R306465

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Apoptosis; HDAC

Type

Reference compound

Related Pathways

Apoptosis; Cell Cycle/DNA Damage; Epigenetics

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/jnj-16241199.html

Purity

99.05

Solubility

DMSO : 11.67 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

O=S(N(CC1)CCN1C2=NC=C(C(NO)=O)C=N2)(C3=CC=C4C(C=CC=C4)=C3)=O

Molecular Formula

C19H19N5O4S

Molecular Weight

413.45

Precautions

H302, H315, H319, H335

References & Citations

[1]Arts J, et al. R306465 is a novel potent inhibitor of class I histone deacetylases with broad-spectrum antitumoral activity against solid and haematological malignancies. Br J Cancer. 2007;97 (10) :1344-1353.